Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Oct 28;18(6):2054-2066.
doi: 10.1016/j.brs.2025.10.023. Online ahead of print.

Human applications of transcranial temporal interference stimulation: A systematic review

Affiliations
Review

Human applications of transcranial temporal interference stimulation: A systematic review

Ilya Demchenko et al. Brain Stimul. .

Abstract

Background: Many neurological and psychiatric disorders involve dysregulation of subcortical structures. Transcranial temporal interference stimulation (tTIS) is a novel, non-invasive method developed to selectively modulate deep brain regions and associated neural circuits.

Methods: A systematic review was conducted to evaluate human applications of tTIS (PROSPERO ID: CRD42024559678). MEDLINE, Embase, APA PsycINFO, CENTRAL, ClinicalTrials.gov, and WHO ICTRP were searched up to December 12, 2024. Studies involving human applications of tTIS were eligible. Methodological quality was appraised using the National Institutes of Health and modified Oxford Centre for Evidence-Based Medicine tools.

Results: Forty-eight records were reviewed (20 published studies, 28 ongoing trials). Of published studies, 16 single-session and 4 multi-session studies assessed safety, mechanistic outcomes, or therapeutic effects of tTIS in 820 participants. Stimulation was most commonly delivered at beta (20 Hz) or gamma (30-130 Hz) envelope frequencies. Neuroimaging studies support target engagement of the motor cortex, basal ganglia, and hippocampus in humans, particularly when stimulation is paired with behavioural tasks. Preliminary clinical findings in small samples demonstrated acute symptom improvements in bradykinesia and tremor within 60 min following a single tTIS session in Parkinson's disease and essential tremor. Reported adverse events across studies were mild (e.g., tingling, itching). Emerging trials increasingly utilize multi-session protocols (2-40 sessions) and are extending tTIS to patients with neurological and psychiatric disorders, particularly epilepsy and depression.

Conclusions: Phase 1 studies demonstrate that tTIS is safe, well-tolerated, and capable of engaging deep brain targets in humans. Well-controlled Phase 2 trials are needed to assess its therapeutic potential in patient populations.

Keywords: Brain; Clinical study; Deep brain stimulation; Electric stimulation; Humans; Systematic review; Temporal interference.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest IT, SC, HY, FG, AR, AK, SK, JAM, SJG, TAS, and SR report no conflicts of interest. ID is a Vanier Scholar supported by the Canadian Institutes of Health Research (award number 513715). AD is an employee of Soterix Medical, Inc. and is supported by the National Institutes of Health (grant numbers 1UG3NS139014–01 and R01EB035129), the National Aeronautics and Space Administration (grant number 80NSSC22CA071), and the United States Department of Defense (grant number W81XWH22C0111). ESB is an inventor on the Temporal Interference (TI) Stimulation patent and a co-founder of TI Solutions GmbH, a for-profit company. IRV is supported by the Biotechnology and Biological Sciences Research Council (grant number BB/S008314/1). RC has received research funding from the Canadian Institutes of Health Research, the Natural Sciences and Engineering Research Council of Canada, the Parkinson Foundation, the National Organization for Rare Disorders, and the Dystonia Medical Research Foundation. He has served as a consultant for AbbVie, Ipsen, and Merz, and participated in a research study sponsored by AbbVie. AML holds the Hudson Chair in Neurosurgery and is a consultant for Abbott, Boston Scientific, and Functional Neuromodulation Inc. VB is supported by an Academic Scholar Award from the Department of Psychiatry at the University of Toronto and has received research support from the Canadian Institutes of Health Research, the Brain & Behavior Research Foundation, the Ontario Ministry of Health Innovation Funds, the Royal College of Physicians and Surgeons of Canada, the Department of National Defence (Government of Canada), the New Frontiers in Research Fund, the American Foundation for Suicide Prevention, the University of Toronto Connaught Fund, the University of Toronto Excellence in Mental Health Seed Fund, and investigator-initiated trials supported by Roche Canada, Eisai Canada, Novartis, Associated Medical Services Inc. Healthcare, and the National Research Council of Canada.

Update of

References

LinkOut - more resources